Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2011

01-03-2011 | Special Article

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

Authors: Lawrence H. Einhorn, Steven M. Grunberg, Bernardo Rapoport, Cynthia Rittenberg, Petra Feyer

Published in: Supportive Care in Cancer | Special Issue 1/2011

Login to get access

Abstract

This paper will evaluate various topics related to chemotherapy-induced nausea and vomiting. The results published reflect a consensus conference convened in Perugia, Italy. The topics discussed include antiemetic therapy of multiple-day chemotherapy, high-dose chemotherapy, and rescue antiemetics.
Literature
1.
Einhorn LH, Rapoport B, Koeller J et al (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Supp Care Cancer 13:112–116CrossRef
2.
Somerfield MR, Einhaus K, Hagerty KL et al (2008) American society of clinical oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol 26:4022–4026PubMedCrossRef
3.
Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of Nabilone over prochlorperazine as antiemetics in patients receiving chemotherapy. N Eng J Med 300:1295–1297CrossRef
4.
Einhorn LH, Nagy C, Werner K et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731–735PubMed
5.
Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391–2395PubMed
6.
Sledge GW, Einhorn LH, Nagy C et al (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524–2528PubMedCrossRef
7.
Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Supp Care Cancer 15:1293–1300CrossRef
8.
Jordan K, Kinitz I, Voigt W et al (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45:1184–1187PubMedCrossRef
9.
Brames MJ, Johnson E, Nichols C et al (2009) Phase III study of granisetron + dexamethasone +/− aprepitant in patients with germ cell tumors undergoing 5 day courses of cisplatin-based combination chemotherapy: a Hoosier Oncology Group (H.O.G.) study. Supp Care Cancer 17:871–872, abstract
10.
Baltzer L, Pisters KMW, Kris MG et al (1993) High dose ondansetron plus dexamethasone for the prevention of nausea and vomiting with multiple day cisplatin chemotherapy. Proc Amer Soc Clin Oncol 12:462, abstract
11.
Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Brit J Cancer 94:1011–1015PubMedCrossRef
12.
Cook AM, Dzik-Jurasz Ask, Padhani AR, Norman A, Huddart RA (2001) The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumors. Brit J Cancer 85:1624–1626PubMedCrossRef
13.
Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ (2001) Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 28:1061–1066PubMedCrossRef
14.
López-Jiménez J, Martín-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R, Fernández C, Calbacho M, García-Belmonte D, Fernández G (2006) Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 91:84–91PubMed
15.
Mandanas RA, Beveridge R, Rifkin RM, Wallace H, Greenspan A, Asmar L (2005) A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapy. Support Cancer Ther 2:114–121PubMedCrossRef
16.
Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O (2009) Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 16:45–51PubMedCrossRef
17.
Musso M, Scalone R, Crescimanno A, Bonanno V, Polizzi V, Porretto F, Bianchini C, Perrone T (2009) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123–127PubMedCrossRef
18.
19.
Choo SP, Kong KH, Lim WT, Gao F, Chua K, Leong SS (2006) Electroacupuncture for refractory acute emesis caused by chemotherapy. J Altern Complement Med 12:963–969PubMedCrossRef
20.
Seynaeve C, de Mulder PH, Lane-Allman E, van Liessum PA, Verweij J (1991) The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Clin Oncol 3:199–203CrossRef
21.
Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F (2008) Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Support Care Cancer 16:1375–1380PubMedCrossRef
22.
Rojas J, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT 3 receptor. Anesth Analg 107:469–478PubMedCrossRef
23.
Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM (2009) Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 17:1065–1070CrossRef
24.
Oechsle K, Muller MR, Hartmann JT, Kanz L, Bokemeyer C (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 19:557–561CrossRef
Metadata
Title
Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement
Authors
Lawrence H. Einhorn
Steven M. Grunberg
Bernardo Rapoport
Cynthia Rittenberg
Petra Feyer
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue Special Issue 1/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0920-z

Other articles of this Special Issue 1/2011

Supportive Care in Cancer 1/2011 Go to the issue

Special Article

Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential

Special Article

Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009

Special Article

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Special Article

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

Special Article

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Meeting Highlight

Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits